Accure Therapeutics was created in 2020 to boost two existing companies in CNS. It integrated IProteos, an IRB Barcelona spin-off created in 2011 and devoted to the research and development of third-generation drugs, based on peptidomimetics (molecules able to modulate the activity of undruggable targets such as Protein-Protein Interactions or PPIs).
Image
